Skip to main content
OpenTrials

Clinical trial condition

Chromosome 17 deletion

Explore clinical trials studying Chromosome 17 deletion. Study availability and eligibility vary by location and protocol.

20 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Chromosome 17 deletion trial results

Completed

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia, +16 more
Locations
  • Norton Cancer Institute /ID# 149788 Louisville, Kentucky, United States
  • St. Agnes Cancer Center /ID# 149782 Baltimore, Maryland, United States
  • Hackensack Univ Med Ctr /ID# 151574 Hackensack, New Jersey, United States
  • Utah Cancer Specialists /ID# 151604 Salt Lake City, Utah, United States
View all 67 locations
View Trial Details
Completed

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

NCT03310190

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia, +15 more
Locations
  • University of Calgary /ID# 166416 Calgary, Alberta, Canada
  • Cross Cancer Institute /ID# 166417 Edmonton, Alberta, Canada
  • Jack Ady Cancer Centre /ID# 217491 Lethbridge, Alberta, Canada
  • CancerCare Manitoba /ID# 170751 Winnipeg, Manitoba, Canada
View all 13 locations
View Trial Details
Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

NCT02980731

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +15 more
Locations
  • Hospital Italiano La Plata /ID# 150812 La Plata, Buenos Aires, Argentina
  • Fundaleu /Id# 150811 Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, Argentina
  • Cemic /Id# 150810 Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, Argentina
  • Sanatorio Allende /ID# 150813 Córdoba, Argentina
View all 33 locations
View Trial Details
Completed

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186

Conditions
17p Deletion, Cancer of the Blood and Bone Marrow, Chromosome 17 deletion, +17 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 96748 Tucson, Arizona, United States
  • City of Hope /ID# 112875 Duarte, California, United States
  • Moore UC San Diego Cancer Center /ID# 91793 La Jolla, California, United States
  • Stanford University School of Med /ID# 105117 Stanford, California, United States
View all 48 locations
View Trial Details
Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045

Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Blood Protein Disorders, +57 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

NCT01392079

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia, +15 more
Locations
  • Hanuschkrankenhaus Wien Vienna, Austria
  • University Hospital Vienna, Austria
  • Centre Hospitalier de la Côte Basque Bayonne, France
  • Hopital Avicenne Bobigny, France
View all 38 locations
View Trial Details
Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT01008462

Conditions
B-Cell Prolymphocytic Leukemia, Blood Protein Disorders, Cardiovascular Diseases, +51 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions